Login / Signup

An Automated, Online Feasibility Randomized Controlled Trial of a Just-In-Time Adaptive Intervention for Smoking Cessation (Quit Sense).

Rupert HarwoodAimie HopeChloë Siegele-BrownKelly GrantGarry BartonCaitlin Jade NotleyCecilia MascoloTim ColemanLee ShepstoneStephen SuttonA Toby PrevostDavid CraneFelix GreavesJuliet High
Published in: Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco (2023)
Running a primarily automated trial to initially evaluate Quit Sense was feasible, resulting in modest recruitment costs and researcher time, and high trial engagement. When invited, as part of trial participation, to install a smoking cessation app, most participants are likely to do so, and, for those using Quit Sense, an estimated one-half will engage with it for more than 1 week. Evidence that Quit Sense may increase verified abstinence at 6-month follow-up, relative to usual care, was generated, although low saliva return rates to verify smoking status contributed to considerable imprecision in the effect size estimate.
Keyphrases
  • smoking cessation
  • study protocol
  • randomized controlled trial
  • replacement therapy
  • phase iii
  • phase ii
  • clinical trial
  • healthcare
  • palliative care
  • open label
  • machine learning
  • pain management
  • double blind
  • single cell